Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Emergent Biosolutions (EBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,041,216
  • Shares Outstanding, K 50,020
  • Annual Sales, $ 560,870 K
  • Annual Income, $ 82,590 K
  • 36-Month Beta 1.23
  • Price/Sales 5.35
  • Price/Cash Flow 21.43
  • Price/Book 3.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.62
  • Number of Estimates 3
  • High Estimate 0.72
  • Low Estimate 0.55
  • Prior Year 0.73
  • Growth Rate Est. (year over year) -15.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.31 +1.91%
on 10/15/18
67.24 -10.11%
on 09/20/18
-4.56 (-7.02%)
since 09/14/18
3-Month
52.83 +14.40%
on 07/30/18
67.24 -10.11%
on 09/20/18
+5.48 (+9.97%)
since 07/13/18
52-Week
36.38 +66.14%
on 11/15/17
67.24 -10.11%
on 09/20/18
+20.13 (+49.94%)
since 10/13/17

Most Recent Stories

More News
Emergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan(R) (Naloxone HCI) Nasal Spray

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Adapt Pharma and its flagship product NARCAN (naloxone HCl) Nasal Spray, the first and only intranasal form...

EBS : 60.44 (-0.59%)
Emergent BioSolutions to Release Third Quarter 2018 Financial Results and Conduct a Conference Call on November 1, 2018

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 1, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2018, recent business...

EBS : 60.44 (-0.59%)
Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up

Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.

EBS : 60.44 (-0.59%)
INO : 5.34 (+0.95%)
VXRT : 3.72 (-4.12%)
SNY : 43.43 (+1.26%)
Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax

Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect...

EBS : 60.44 (-0.59%)
21.1% Return Seen to Date on SmarTrend Emergent Biosolu Call (EBS)

SmarTrend identified an Uptrend for Emergent Biosolu (NYSE:EBS) on July 12th, 2018 at $54.41. In approximately 3 months, Emergent Biosolu has returned 21.11% as of today's recent price of $65.89.

EBS : 60.44 (-0.59%)
Uptrend Call Working As Emergent Biosolu Stock Rises 20.3% (EBS)

SmarTrend identified an Uptrend for Emergent Biosolu (NYSE:EBS) on July 12th, 2018 at $54.41. In approximately 3 months, Emergent Biosolu has returned 20.30% as of today's recent price of $65.45.

EBS : 60.44 (-0.59%)
Factors of Influence in 2018, Key Indicators and Opportunity within Emergent Biosolutions, LGI Homes, Surgery Partners, Overseas Shipholding Group, National Commerce, and comScore -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Emergent Biosolutions Inc....

OSG : 3.35 (+0.60%)
SCOR : 16.90 (-2.03%)
EBS : 60.44 (-0.59%)
NCOM : 39.93 (+1.50%)
LGIH : 38.78 (-0.05%)
OPHLY : 8.4000 (-4.33%)
SGRY : 14.20 (+3.65%)
Emergent (EBS) to Buy Narcan Maker Adapt Pharma for $735M

Emergent (EBS) inks a deal to buy Adapt Pharma. This move will add the latter's popular Narcan nasal spray to its portfolio.

ILMN : 313.41 (-2.57%)
EBS : 60.44 (-0.59%)
GSK : 38.88 (+1.49%)
SNY : 43.43 (+1.26%)
Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences

Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company's senior management team will participate in the following investor conferences during the third quarter and early portion...

EBS : 60.44 (-0.59%)
CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine

OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioSciences,...

EBS : 60.44 (-0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade EBS with:

Business Summary

Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining...

See More

Key Turning Points

2nd Resistance Point 62.06
1st Resistance Point 61.25
Last Price 60.44
1st Support Level 59.47
2nd Support Level 58.50

See More

52-Week High 67.24
Last Price 60.44
Fibonacci 61.8% 55.45
Fibonacci 50% 51.81
Fibonacci 38.2% 48.17
52-Week Low 36.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar